New trial
Phase 1 study of naxitamab GD2-directed monoclonal antibody in neuroblastoma
- Trial ID
- NCT07027748 on ClinicalTrials.gov
- Cancer type
- Neuroendocrine Tumor
- Stage of research
- Exploratory
- Published in
- New in Oncology - July 3, 2025
This trial uses a modified 3+3 design to assess the optimal naxitamab infusion duration with irinotecan, temozolomide, and sargramostim in patients with relapsed or refractory neuroblastoma or ganglioneuroblastoma. It explores whether slower naxitamab infusions can reduce treatment-related toxicities.
More in neuroendocrine and adrenal tumors
-
Trial result · Oct 15, 2026 · NCT00107289
Single ¹³¹I-MIBG (NET-targeted radiopharmaceutical) + single autologous stem cell rescue shows feasible engraftment but low response in resistant neuroblastoma -
Trial result · Aug 27, 2026 · NCT03972488
¹⁷⁷Lu-DOTATATE (SSTR-targeted PRRT) extends PFS ~14 months vs high-dose octreotide in 1L G2–G3 GEP-NETs -
New trial · Aug 27, 2026 · NCT07743138
Phase 2 ivonescimab PD-1×VEGF bispecific antibody in previously treated ACC/PPGL -
Trial result · Aug 6, 2026 · NCT03049189
[177Lu]Lu-edotreotide (SSTR2-targeted PRRT) beats everolimus on PFS in progressive GEP-NETs (COMPETE) -
New trial · Jul 16, 2026 · NCT07661420
Phase 1 211At‑MABG targeted alpha radiotherapy (NET/norepinephrine transporter–avid) in advanced NETs